AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. / Hatse, Sigrid; Princen, Katrien; De Clercq, Erik; Rosenkilde, Mette M; Schwartz, Thue W; Hernandez-Abad, Pedro E; Skerlj, Renato T; Bridger, Gary J; Schols, Dominique.

In: Biochemical Pharmacology, Vol. 70, No. 5, 2005, p. 752-61.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hatse, S, Princen, K, De Clercq, E, Rosenkilde, MM, Schwartz, TW, Hernandez-Abad, PE, Skerlj, RT, Bridger, GJ & Schols, D 2005, 'AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor', Biochemical Pharmacology, vol. 70, no. 5, pp. 752-61. https://doi.org/10.1016/j.bcp.2005.05.035

APA

Hatse, S., Princen, K., De Clercq, E., Rosenkilde, M. M., Schwartz, T. W., Hernandez-Abad, P. E., Skerlj, R. T., Bridger, G. J., & Schols, D. (2005). AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochemical Pharmacology, 70(5), 752-61. https://doi.org/10.1016/j.bcp.2005.05.035

Vancouver

Hatse S, Princen K, De Clercq E, Rosenkilde MM, Schwartz TW, Hernandez-Abad PE et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochemical Pharmacology. 2005;70(5):752-61. https://doi.org/10.1016/j.bcp.2005.05.035

Author

Hatse, Sigrid ; Princen, Katrien ; De Clercq, Erik ; Rosenkilde, Mette M ; Schwartz, Thue W ; Hernandez-Abad, Pedro E ; Skerlj, Renato T ; Bridger, Gary J ; Schols, Dominique. / AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. In: Biochemical Pharmacology. 2005 ; Vol. 70, No. 5. pp. 752-61.

Bibtex

@article{c9a868c09d2d11debc73000ea68e967b,
title = "AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor",
abstract = "The chemokine receptors CCR5 and CXCR4 function as coreceptors for human immunodeficiency virus (HIV) and are attractive targets for the development of anti-HIV drugs. The most potent CXCR4 antagonists described until today are the bicyclams. The prototype compound, AMD3100, exhibits potent and selective anti-HIV activity against CXCR4-using (X4) viruses and showed antiviral efficacy in X4 HIV-1-infected persons in a phase II clinical trial. However, AMD3100 lacks oral bioavailability due to its high overall positive charge. Initial structure-activity relationship studies with bicyclam analogues suggested that the bis-macrocyclic structure was a prerequisite for anti-HIV activity. Now, we report that the N-pyridinylmethylene cyclam AMD3465, which lacks the structural constraints mentioned above, fully conserves all the biological properties of AMD3100. Like AMD3100, AMD3465 blocked the cell surface binding of both CXCL12 (the natural CXCR4 ligand), and the specific anti-CXCR4 monoclonal antibody 12G5. AMD3465 dose-dependently inhibited intracellular calcium signaling, chemotaxis, CXCR4 endocytosis and mitogen-activated protein kinase phosphorylation induced by CXCL12. Compared to the bicyclam AMD3100, AMD3465 was even 10-fold more effective as a CXCR4 antagonist, while showing no interaction whatsoever with CCR5. As expected, AMD3465 proved highly potent against X4 HIV strains (IC50: 1-10 nM), but completely failed to inhibit the replication of CCR5-using (R5) viruses. In conclusion, AMD3465 is a novel, monomacrocyclic anti-HIV agent that specifically blocks the interaction of HIV gp120 with CXCR4. Although oral bioavailability is not yet achieved, the monocyclams, with their decreased molecular charge as compared to the bicyclams, embody an important step forward in the design of oral CXCR4 antagonists that can be clinically used as anti-HIV drugs.",
author = "Sigrid Hatse and Katrien Princen and {De Clercq}, Erik and Rosenkilde, {Mette M} and Schwartz, {Thue W} and Hernandez-Abad, {Pedro E} and Skerlj, {Renato T} and Bridger, {Gary J} and Dominique Schols",
note = "Keywords: Anti-HIV Agents; Cell Line; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Dose-Response Relationship, Drug; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Receptors, CXCR4; Signal Transduction",
year = "2005",
doi = "10.1016/j.bcp.2005.05.035",
language = "English",
volume = "70",
pages = "752--61",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

AU - Hatse, Sigrid

AU - Princen, Katrien

AU - De Clercq, Erik

AU - Rosenkilde, Mette M

AU - Schwartz, Thue W

AU - Hernandez-Abad, Pedro E

AU - Skerlj, Renato T

AU - Bridger, Gary J

AU - Schols, Dominique

N1 - Keywords: Anti-HIV Agents; Cell Line; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Dose-Response Relationship, Drug; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Receptors, CXCR4; Signal Transduction

PY - 2005

Y1 - 2005

N2 - The chemokine receptors CCR5 and CXCR4 function as coreceptors for human immunodeficiency virus (HIV) and are attractive targets for the development of anti-HIV drugs. The most potent CXCR4 antagonists described until today are the bicyclams. The prototype compound, AMD3100, exhibits potent and selective anti-HIV activity against CXCR4-using (X4) viruses and showed antiviral efficacy in X4 HIV-1-infected persons in a phase II clinical trial. However, AMD3100 lacks oral bioavailability due to its high overall positive charge. Initial structure-activity relationship studies with bicyclam analogues suggested that the bis-macrocyclic structure was a prerequisite for anti-HIV activity. Now, we report that the N-pyridinylmethylene cyclam AMD3465, which lacks the structural constraints mentioned above, fully conserves all the biological properties of AMD3100. Like AMD3100, AMD3465 blocked the cell surface binding of both CXCL12 (the natural CXCR4 ligand), and the specific anti-CXCR4 monoclonal antibody 12G5. AMD3465 dose-dependently inhibited intracellular calcium signaling, chemotaxis, CXCR4 endocytosis and mitogen-activated protein kinase phosphorylation induced by CXCL12. Compared to the bicyclam AMD3100, AMD3465 was even 10-fold more effective as a CXCR4 antagonist, while showing no interaction whatsoever with CCR5. As expected, AMD3465 proved highly potent against X4 HIV strains (IC50: 1-10 nM), but completely failed to inhibit the replication of CCR5-using (R5) viruses. In conclusion, AMD3465 is a novel, monomacrocyclic anti-HIV agent that specifically blocks the interaction of HIV gp120 with CXCR4. Although oral bioavailability is not yet achieved, the monocyclams, with their decreased molecular charge as compared to the bicyclams, embody an important step forward in the design of oral CXCR4 antagonists that can be clinically used as anti-HIV drugs.

AB - The chemokine receptors CCR5 and CXCR4 function as coreceptors for human immunodeficiency virus (HIV) and are attractive targets for the development of anti-HIV drugs. The most potent CXCR4 antagonists described until today are the bicyclams. The prototype compound, AMD3100, exhibits potent and selective anti-HIV activity against CXCR4-using (X4) viruses and showed antiviral efficacy in X4 HIV-1-infected persons in a phase II clinical trial. However, AMD3100 lacks oral bioavailability due to its high overall positive charge. Initial structure-activity relationship studies with bicyclam analogues suggested that the bis-macrocyclic structure was a prerequisite for anti-HIV activity. Now, we report that the N-pyridinylmethylene cyclam AMD3465, which lacks the structural constraints mentioned above, fully conserves all the biological properties of AMD3100. Like AMD3100, AMD3465 blocked the cell surface binding of both CXCL12 (the natural CXCR4 ligand), and the specific anti-CXCR4 monoclonal antibody 12G5. AMD3465 dose-dependently inhibited intracellular calcium signaling, chemotaxis, CXCR4 endocytosis and mitogen-activated protein kinase phosphorylation induced by CXCL12. Compared to the bicyclam AMD3100, AMD3465 was even 10-fold more effective as a CXCR4 antagonist, while showing no interaction whatsoever with CCR5. As expected, AMD3465 proved highly potent against X4 HIV strains (IC50: 1-10 nM), but completely failed to inhibit the replication of CCR5-using (R5) viruses. In conclusion, AMD3465 is a novel, monomacrocyclic anti-HIV agent that specifically blocks the interaction of HIV gp120 with CXCR4. Although oral bioavailability is not yet achieved, the monocyclams, with their decreased molecular charge as compared to the bicyclams, embody an important step forward in the design of oral CXCR4 antagonists that can be clinically used as anti-HIV drugs.

U2 - 10.1016/j.bcp.2005.05.035

DO - 10.1016/j.bcp.2005.05.035

M3 - Journal article

C2 - 16011832

VL - 70

SP - 752

EP - 761

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -

ID: 14305521